Overall, we confirmed our hypothesis that AF-mediated oxidative stress induction in combination with olaparib-mediated PARP inhibition could induce a cytotoxic and synergistic response against mutant p53 cancers in vitro and a reduction of tumor growth in vivo. Here, PARP1 is linked to neoplasm.